

# MALARIA VACCINE PILOTS AND LONG-TERM SUPPLY

---

BOARD MEETING

**Aurélia Nguyen**

4-5 December 2019, Delhi, India



Reach every child

[www.gavi.org](http://www.gavi.org)

# Funding required to complete malaria pilots and enable policy and investment decision-making

## 2017-2020

- Gavi committed US\$ 24.6m in 2016
- Matched by Global Fund (US\$ 15m) and Unitaid (US\$ 9.6m)

## 2021-2023

- Unitaid committed US\$ 3.6m in 2016
- GF approved up to US\$ 8m in May
- **Gavi request: US\$ 11.6m (match GF and Unitaid)**

# Impending manufacturing decision has long-term implications


## Short-term supply context

- GSK: 10m donation doses for MVIP
- Manufacturing site re-commissioned, production of donation doses complete end 2020
- Stop or continue production?

## Long-term supply context


- GSK: facility to cease antigen supply in 2028
- Product transfer to lower cost manufacturer
- Separate funding / financing mechanism required: product transfer, scale-up adjuvant

# Two RTS,S production scenarios have different indicative timelines...



# ...with have long-term implications for supply

*Illustrative*



# The two production scenarios have different programmatic and financial trade-offs


## Stop production scenario

- + No financing at risk
- + Defer further investment until additional data / policy rec'd
- ~3 year delay in introduction, slower scale-up
- Risk to programme continuity
- Risk successful product transfer
- Negative signal for R&D

## Continue production scenario

- + Faster introduction (up to ~40k additional lives saved through 2028)
- + Programme continuity
- + Potential future price reduction
- Financial liability (US\$ 25-75m)
- Opportunity cost
- Funding at risk: future programme not assured


# Gavi engagement: two options presented to PPC, third has been explored at PPC request



**1. No financial  
guarantee**



**2. Gavi shares  
risk with GSK**



**3. Identify 3<sup>rd</sup>  
party to share  
risk**

# Recommendation (1/3): Malaria vaccine pilots

---

The Gavi Alliance Programme and Policy Committee **recommends** to the Gavi Alliance Board that it:

- a) **Approve** an amount up to US\$ 11.6 million to continue the malaria vaccine implementation programme from 2021-2023;



## Recommendation (2/3): Long-term malaria vaccine supply

The Gavi Alliance Programme and Policy Committee **recommends** to the Gavi Alliance Board that it:

EITHER:

### Option 1

- b) **Defer** providing an investment for continued production of RTS,S bulk antigen pending a WHO policy decision and Gavi investment case for broader roll-out;

OR:

### Option 2

- c) **Approve** providing an investment for continued production of RTS,S bulk antigen pending a WHO policy decision and Gavi investment case for broader roll-out; and
- d) **Note** that the Market Sensitive Decisions Committee will make a final determination of  
9 the structure of the investment.

# Recommendation (3/3): Long-term malaria vaccine supply

---

OR:

## Option 3

- e) **Request** the Secretariat to work with stakeholders to identify third-parties to cost share whereby Gavi's financial risk should be minimised or reduced to zero to provide for an investment for continued production of RTS,S bulk antigen pending a WHO policy decision and Gavi investment case for broader roll-out; and
- f) **Approve** an investment for continued production of RTS,S bulk antigen between Gavi and third-parties whereby Gavi's financial risk exposure should be minimised as much as possible, with reassessment of support on an annual basis, subject to the final terms being reviewed and endorsed by the Market Sensitive Decisions Committee.

# THANK YOU

---



Reach every child

[www.gavi.org](http://www.gavi.org)